In AVAC Report 2012, Achieving the End: One Year and Counting we’ve identified five priorities for action.
Achieving the End: One Year and Counting
Achieving the End
Recent breakthroughs in HIV prevention research have created unprecedented opportunities to curb new HIV infections, save lives and set the world on a path towards eliminating HIV transmission.
Plans and Missing Pieces in PrEP Demonstration Projects: USA
This infographic from AVAC Report 2012 identifies the design and key questions for ongoing or planned PrEP demonstration projects in the US.
Reaching the Tipping Point: The time to act is now
AVAC Playbook 2012-2013: Progress toward global goals
AVAC first published its Playbook of global goals for ending AIDS in late 2011. This infographic from the AVAC Report 2012 builds on the objectives from 2011 and identifies five priorities for action in 2013.
Momentum for PrEP and Other News from USCA
In October, AVAC’s Kevin Fisher and Deirdre Grant and a number of PxROAR program members descended on Las Vegas for the United States Conference on AIDS (USCA). USCA is a US-focused conference that largely attracts front-line providers from AIDS service organizations.
This was AVAC’s fourth year presenting on PrEP at USCA, but importantly the first time since the United States FDA approved an indication for daily oral TDF/FTC (Truvada) as PrEP in July. Kevin and Deirdre led a seminar session PrEP can protect women and men against HIV! What do we need to know and do so we can translate results into public health impact? Over 75 people engaged in discussions on the state of PrEP research/implementation—the largest audience AVAC has had for this type of session at USCA—highlighting the growing need for information about PrEP, especially in translating research to rollout.
The audience participated in an energetic debate about whether at next year’s USCA, they thought they would be talking about how their communities had integrated PrEP into local HIV prevention efforts. In a reversal from previous years, almost everyone in the room was supportive of the idea that PrEP would be a part of their local prevention efforts. Previous questions surrounding PrEP have begun to be answered and its potential as a new—and needed—HIV prevention option is seen.
PxROAR members were also busy at USCA. Nichole Little led a roundtable discussion on PrEP and women based largely on her ROAR work—Sex, Biomedical HIV Prevention & The New Millennium Woman: Is PrEP The Answer For Me? Kieta Mutepfa helped facilitate a session on Strategies for HIV Prevention Message Development in Specialized Populations: A Case Study of Empowering Young MSM of Color in Los Angeles as Advocates for PrEP. Ebony Johnson was a speaker at the Opening Plenary Breakfast addressing what can be done to turn the tide of the epidemic among women and ensure social and health equity for all women in the United States.
The Change We Need to End AIDS in Uganda
2012 AVAC Fellow Alice Kayongo played a leading role in developing a civil society report, “The Change We Need to End AIDS in Uganda”, which details concerns and recommendations for shaping the national AIDS response in Uganda. This report was presented at the Joint Annual Review (JAR) of the country’s five-year National Strategic Plan (NSP) for responding to HIV/AIDS, which was first launched about a year ago. The mid-October JAR meeting was an opportunity to review progress and gaps. In the weeks leading up to the JAR, civil society participated in reviews of draft assessments of progress on the various elements of the NSP, including prevention, treatment and care, and health systems strengthening.
Kayongo was joined in this coalition effort by Sylvia Nakasi and Bharam Namanya of UNASO (2011 Fellow and Host Supervisor, respectively), and Leonard Okello, Alice’s Fellowship supervisor and Lillian Mworeko of ICW-EA (2012 Host)—as well as a broad range of other advocates.
The report, presented at the JAR, included a 10-point plan to halt new infections, save lives and ensure leadership, and provided a detailed critique of the national AIDS response to date.
This advocacy comes on the heels of a dynamic and successful campaign to increase funding for and recruitment of more than 6,000 health care workers throughout Uganda.
For a copy of the report, reach out to [email protected].
Press Release
AVAC statement on PEPFAR Blueprint
New York, NY – PEPFAR’s blueprint has enormous potential to accelerate global HIV prevention efforts. It rightly emphasizes that we need to ‘follow the science’ if we intend to deliver life-saving HIV prevention and treatment breakthroughs to millions of people worldwide. The blueprint underscores that success depends on scaling up combinations of effective strategies. It also places much-needed emphasis on voluntary medical male circumcision, which could prevent millions of HIV infections and do so more affordably than almost any other method today.
It’s particularly encouraging that the blueprint focuses on translating scientific breakthroughs into lives saved. Powerful new HIV prevention options could together lead to dramatic reductions in HIV infections, but we don’t have all the information we need to scale them up in the right combinations for various communities. Urgent questions about the real-world use of new prevention tools in combination have been clear for months or even years, yet the work to answer them is barely under way. That’s as unconscionable as it is unnecessary.
The blueprint also recognizes that ending AIDS will not be easy or quick. While current options can have a tremendous impact, continued science and innovation are essential to ultimately halt new HIV infections and deaths from AIDS.
The US has shown great leadership, and now it’s time for the rest of the global community to step up. Frankly, we are not on pace to end AIDS – but we could be. Global agencies, governments, donors and advocates need to work with PEPFAR now to agree on the most urgent priorities, set specific goals and demonstrate real progress within the next year.
A PDF version of this is available for download.
Contact:
Mitchell Warren, [email protected], +1-914-661-1536
###
About AVAC: Founded in 1995, AVAC is a non-profit organization that uses education, policy analysis, advocacy and a network of global collaborations to accelerate the ethical development and global delivery of AIDS vaccines, male circumcision, microbicides, PrEP and other emerging HIV prevention options as part of a comprehensive response to the pandemic.
Press Release
AVAC report finds that world is already falling behind pace to end AIDS epidemic; five essential actions needed in 2013 to avoid historic missed opportunity
New York, NY – AVAC today issued a “top five” list of global actions needed in 2013 to accelerate HIV prevention efforts and preserve the opportunity to end the AIDS epidemic. The recommendations address urgent, unresolved challenges that threaten the delivery of powerful new HIV prevention methods that could help dramatically reduce the 2.5 million new HIV infections that occur worldwide every year. They include critical actions to speed access to HIV treatment, voluntary medical male circumcision (VMMC) and pre-exposure prophylaxis (PrEP), and to safeguard vital new research on vaccines, microbicides, other HIV prevention options and a cure.
“Recent scientific breakthroughs give us reason to be optimistic like never before, but our chances of success are already imperiled,” said Mitchell Warren, AVAC executive director. “Right now, the world isn’t moving as fast as it should be to begin ending the epidemic. There is still time to get back on a winning pace but only with focused, aggressive action now. This can be the year that HIV prevention begins to achieve its potential – in fact, it has to be.”
The priorities are featured in a new report, Achieving the End: One Year and Counting, which offers AVAC’s critical assessment of progress achieved since global leaders began to discuss the opportunity to “begin to end AIDS” in late 2011. The report reflects input from HIV prevention leaders across a broad spectrum.
“We have a narrow window to translate the past year’s excitement into life-saving changes on the ground,” said Dr. Helen Rees, Executive Director of the Wits Reproductive Health and HIV Institute (WRHI) in South Africa and a member of AVAC’s board of directors. “The possibility of ending AIDS is very much alive but depends on much bolder leadership, increased coordination and agreement on a clear set of short-term priorities.”
“The world needs immediate answers to the question, ‘What now?’, and then it needs to act on them,” said Warren. “We’ve identified what we believe are the five HIV prevention priorities that can make the greatest possible difference in the coming year. Whether we’re on pace to end AIDS in a year’s time will depend in large part on our success in these areas.”
AVAC’s priority recommendations for 2013 are as follows:
- End confusion about “combination prevention” – In 2012, there was long-overdue recognition that different countries will need to implement different combinations of HIV prevention interventions for different populations at risk. But the hard work of defining those combinations and establishing priorities has not been done. In 2013, donors, policy makers and civil society need to be held accountable for choosing, implementing and evaluating the right packages of interventions for specific circumstances.
- Close the gaps in the HIV “treatment cascade” – Antiretroviral treatment not only improves and prolongs the lives of those infected, it is among the most powerful HIV prevention strategies available, reducing the risk that an infected person will pass on HIV by up to 96 percent. But only a small proportion of people diagnosed with HIV are linked to antiretroviral treatment and an even smaller share stay on treatment and have their HIV infection suppressed to levels low enough to prevent transmission to others. A range of studies is looking at ways to narrow this gap, but these efforts are uncoordinated and incomplete. In 2013, researchers and funders need to convene and establish a clear research and implementation agenda to close the gaps in the treatment cascade.
- Prepare for new non-surgical male circumcision devices – In 2013, the World Health Organization (WHO) is expected to approve new male circumcision devices that could eliminate the need for surgery, speed recovery and lower costs in many of the 14 priority African countries where VMMC could reduce HIV infections by 20 percent. While the new devices may not be right for every country or setting, there could be months or years of lost opportunities unless national health leaders immediately take action to evaluate their benefits, costs and optimal uses.
- Define and roll out needed PrEP demonstration projects – Global health agencies including WHO and UNAIDS have said they are awaiting the results of real-world demonstration projects before they can provide guidance on the use of PrEP – yet there is no clarity on what range of studies is needed, and few are under way. By the end of 2013, a core set of studies must be defined and moving ahead.
- Safeguard HIV prevention research funding – New momentum on research into HIV vaccines, microbicides and other new tools is threatened due to the possibility of federal budget sequestration in the US and similar pressures in other countries. The potential cuts could slow or halt progress on some of the most promising HIV prevention research in many years. Policy makers must have the courage to preserve this vital research in 2013.
“The most urgent questions about new prevention tools have been clear for months or even years, and yet the work to answer them is barely under way,” said Warren. “That’s as unconscionable as it is unnecessary. Millions of lives depend on our ability to pick up the pace.”
The new recommendations build on AVAC’s long-term agenda for global HIV prevention efforts, issued in late 2011. That report, titled simply The End?, established near-, medium- and long-term goals for delivering available prevention interventions, demonstrating potential impact of emerging tools such as PrEP and microbicides, and developing essential new tools, including AIDS vaccines. In addition to the five key priorities for 2013, AVAC’s new report includes key updates to the long-term agenda for global HIV prevention.
A PDF version of this press release is available.
Contact:
Mitchell Warren, [email protected], +1-914-661-1536
Kay Marshall, [email protected], +1-347-249-6375
###
About AVAC: Founded in 1995, AVAC is a non-profit organization that uses education, policy analysis, advocacy and a network of global collaborations to accelerate the ethical development and global delivery of AIDS vaccines, male circumcision, microbicides, PrEP and other emerging HIV prevention options as part of a comprehensive response to the pandemic.
PrEP for Women — What’s the Plan?
Just days before the start of the International AIDS Conference, the US Food and Drug Administration announced its approval of TDF/FTC for pre-exposure prophylaxis (PrEP). This development has raised hopes, questions and concerns on many fronts. A session in the Global Village at AIDS 2012, “How can ARVs as prevention work for HIV-negative women?”, looked specifically at women’s views on this potential new prevention tool. Over 30 participants, most of whom were women, discussed current and future options for using ARVs for prevention in HIV-negative women. The session was co-facilitated by Lisa Diane White of SisterLove (and a PxROAR member) and Manju Chatani-Gada of AVAC.
The animated dialogue started with a presentation on HPTN 064, also known as ISIS, a US government-funded study designed to estimate the overall new HIV infection rate for women at risk in the US. Through focus groups and in-depth interviews, this research identified a number of barriers to HIV prevention and risk factors affecting these women. The discussion then shifted to one potential new prevention tool for women—daily oral TDF/FTC as PrEP. After a review of the data and current regulatory developments, the audience discussed what PrEP might mean for US women. Participants raised many questions including who would pay, how much PrEP would cost, what types of programs would offer PrEP to HIV-negative women and what kinds of testing would be required.
Similar questions apply internationally. Look out for more opportunities to join the US and international-based conversations led by AVAC and its partners.